DermatologyInvestigational

Matrixyl 3000

Topical

Overview

Matrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The formulation is designed to synergistically promote collagen and fibronectin synthesis while reducing interleukin-6 mediated inflammation in dermal fibroblasts.

Mechanism of Action

Both peptides carry palmitic acid for enhanced lipid solubility and stratum corneum permeation..

Research Summary & Key Findings

Preclinical fibroblast assays have shown that the combination upregulates matrix protein gene expression and reduces IL-6 secretion in models of cellular senescence. Industry-sponsored clinical trials have reported reductions in wrinkle surface area and improved dermal density via ultrasound imaging after 8 to 12 weeks of topical application. Independent replication and publication in indexed dermatology journals remain limited.

Clinical Status

Investigational

Matrixyl 3000 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers Matrixyl 3000 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Matrixyl 3000.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.